GSK pays $625M for Cambridge biotech's cancer antibody

Shares of iTeos Therapeutics jumped by nearly 40% on the news that it has licensed its cancer antibody to pharmaceutical giant GlaxoSmithKline, which is paying $625 million up front for the drug.